Login Register Cart 0
Generic placeholder image

Coronaviruses

Editor-in-Chief

ISSN (Print): 2666-7967
ISSN (Online): 2666-7975

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Letter Article

Repurposing of RdRp Inhibitors against SARS-CoV-2 through Molecular Docking Tools

Author(s): Rohit Bhatia*, Raj Kumar Narang and Ravindra Kumar Rawal

Volume 1, Issue 1, 2020

Page: [108 - 116] Pages: 9

DOI: 10.2174/2666796701999200617155629

Abstract

In the present hour, the COVID-19 pandemic needs no introduction. There is continuous and keen research in progress in order to discover or develop a suitable therapeutic candidate/vaccine against the fatal, severe acute respiratory syndrome causing coronavirus (SARS-CoV-2). Drug repurposing is an approach of utilizing the therapeutic potentials of previously approved drugs against some new targets or pharmacological responses. In the presented work, we have evaluated the RNA dependent RNA polymerase (RdRp) inhibitory potentials of FDA approved anti-viral drugs remdesivir, ribavirin, sofosbuvir and galidesivir through molecular docking. The studies were carried out using MOE 2019.0102 software against RdRp (PDB ID:7BTF, released on 8th April, 2020). All four drugs displayed good docking scores and significant binding interactions with the amino acids of the receptor. The docking protocol was validated by redocking of the ligands and the root mean square deviation (RMSD) value was found to be less than 2. The 2D and 3D binding patterns of the drugs were studied and evaluated with the help of poses. The drugs displayed excellent hydrogen bonding interactions within the cavity of the receptor and displayed comparable docking scores. These drugs may serve as new therapeutic candidates or leads against SARS-CoV-2.

Keywords: COVID-19, SARS-CoV-2, remdesivir, ribavirin, sofosbuvir, galidesivir.

[1]
Anthony SJ, Johnson CK, Greig DJ, et al. PREDICT Consortium. Global patterns in coronavirus diversity. Virus Evol 2017; 3(1)vex012
[http://dx.doi.org/10.1093/ve/vex012] [PMID: 28630747]
[2]
Prajapat M, Sarma P, Shekhar N, et al. Drug targets for corona virus: A systematic review. Indian J Pharmacol 2020; 52(1): 56-65.
[http://dx.doi.org/10.4103/ijp.IJP_115_20] [PMID: 32201449]
[3]
Hilgenfeld R. From SARS to MERS: Crystallographic studies on corona viral proteases enable antiviral drug design. FEBS J 2014; 281: 4085-96.
[4]
Wang H, Xue S, Yang H, Chen C. Recent progress in the discovery of inhibitors targeting coronavirus proteases. Virol Sin 2016; 31(1): 24-30.
[http://dx.doi.org/10.1007/s12250-015-3711-3] [PMID: 26920707]
[5]
Bhatia R, Narang RK, Rawal RK. A summary of viral targets and recently released PDB IDs of SARS-CoV-2. Open Virol J 2020; 14: 7-8.
[http://dx.doi.org/10.2174/1874357902014010007]
[6]
Ng KK, Arnold JJ, Cameron CE. Structure-function relationships among RNA-dependent RNA polymerases. Curr Top Microbiol Immunol 2008; 320: 137-56.
[http://dx.doi.org/10.1007/978-3-540-75157-1_7] [PMID: 18268843]
[7]
Xu X, Liu Y, Weiss S, Arnold E, Sarafianos SG, Ding J. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res 2003; 31(24): 7117-30.
[http://dx.doi.org/10.1093/nar/gkg916] [PMID: 14654687]
[8]
De Clercq E. Antivirals and antiviral strategies. Nat Rev Microbiol 2004; 2(9): 704-20.
[http://dx.doi.org/10.1038/nrmicro975] [PMID: 15372081]
[9]
Cheng F, Murray JL, Rubin DH. Drug repurposing: new treatments for Zika virus infection? Trends Mol Med 2016; 22(11): 919-21.
[http://dx.doi.org/10.1016/j.molmed.2016.09.006] [PMID: 27692879]
[10]
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study. Life Sci 2020; 253117592
[http://dx.doi.org/10.1016/j.lfs.2020.117592] [PMID: 32222463]
[11]
Gordon CJ, Tchesnokov EP, Feng JY, Porter DP, Götte M. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020; 295(15): 4773-9.
[http://dx.doi.org/10.1074/jbc.AC120.013056] [PMID: 32094225]
[12]
Tchesnokov EP, Raeisimakiani P, Ngure M, Marchant D, Götte M. Recombinant RNA-dependent RNA polymerase complex of Ebola Virus. Sci Rep 2018; 8(1): 3970.
[http://dx.doi.org/10.1038/s41598-018-22328-3] [PMID: 29507309]
[13]
Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382(24): 2327-36.
[http://dx.doi.org/10.1056/NEJMoa2007016] [PMID: 32275812]
[14]
Ahmed-Belkacem A, Guichou JF, Brillet R, et al. Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention. Nucleic Acids Res 2014; 42(14): 9399-409.
[http://dx.doi.org/10.1093/nar/gku632] [PMID: 25053847]
[15]
Kirchdoerfer RN, Ward AB. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. Nat Commun 2019; 10(1): 2342.
[http://dx.doi.org/10.1038/s41467-019-10280-3] [PMID: 31138817]
[16]
Gao Y, Yan L, Huang Y, et al. SARS-CoV-2 RNA-dependent RNA polymerase in complex with cofactors in reduced condition. 2020.
[17]
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11(1): 222.
[http://dx.doi.org/10.1038/s41467-019-13940-6] [PMID: 31924756]
[18]
Guo D. Old weapon for new enemy: drug repurposing for treatment of newly emerging viral diseases. Virol Sin 2020.
[http://dx.doi.org/10.1007/s12250-020-00204-7] [PMID: 32048130]
[19]
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020; 21(5): 730-8.
[http://dx.doi.org/10.1002/cbic.202000047] [PMID: 32022370]
[20]
Maxmen A. More than 80 clinical trials launch to test coronavirus treatments. Nature 2020; 578(7795): 347-8.
[http://dx.doi.org/10.1038/d41586-020-00444-3] [PMID: 32071447]
[21]
Elfiky AA. The antiviral Sofosbuvir against mucormycosis: an in silico perspective. Future Virology 2019; 14: 739-44.
[22]
Warren TK, Wells J, Panchal RG, et al. Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 2014; 508(7496): 402-5.
[http://dx.doi.org/10.1038/nature13027] [PMID: 24590073]
[23]
Protein Data Bank. https://www.rcsb.org/structure/7BTF

Rights & Permissions Print Cite
Article Metrics
23
2
© 2024 Bentham Science Publishers | Privacy Policy